The FDA has delayed a decision on Biogen Idec's hemophilia B therapy Alprolix.
The new CEO at Forest Laboratories is committing to what has become a common ritual in the industry, gearing up for a major reorganization with a special focus on slashing research costs.
A few days after the feds left Seattle-based Theraclone Sciences high and dry of funds for its midstage study of an antiflu antibody, PharmAthene is now spreading the word that it is backing out of its planned merger with the biotech.
Eisai announced late last week that it is bringing the ax down on its R&D facility in Andover, MA, and other research centers around the globe as it chops 130 staffers out of its operations.
As Visterra readies an influenza antibody for Phase I trials, the Gates-foundation-backed biotech announced today it's hired veterans of Mascoma and Concert Pharmaceuticals and licensed an antibody to treat the dengue virus out of the MIT lab of its co-founder, Dr. Ram Sasisekharan.
The most popular stories and special reports in FierceBiotech Research, FiercePharmaManufacturing, and the rest of our Life Sciences publications
This year's examination of our top 5 stories of the year says a lot about what works when you're creating a presence on the world wide web and how it can also deliver super-sized audiences on some odd bits of work.
Belgium's Galapagos NV says that GlaxoSmithKline is prepping a Phase II study of GSK2586184 (formerly GLPG0778)--its JAK1 inhibitor--for ulcerative colitis.
Theraclone Sciences was hoping for a federal cash infusion to keep its anti-influenza antibody program rolling, but a denial from the government will force the biotech to handle Phase II on its own.
Teva may not have actually planted a "for sale" sign on its front yard, but now that CEO Jeremy Levin has left the scene of many accidents some top analysts are offering to advertise it as a takeover candidate.
GlaxoSmithKline is broadening its reach in the big U.S. R&D field in coming months, ramping up satellite innovation centers in Cambridge, MA, and San Diego where its teams can shepherd a growing flock of research partnerships while hunting down new technologies and spawning biotech startups.
A few months after Jennerex and its partner Transgene reported that their oncolytic cancer vaccine Pexa-Vec flunked a Phase IIb endpoint on overall survival in liver cancer, the private South Korean CRO SillaJen has stepped in to buy the company in a deal worth up to $150 million at the high end.
While the venture capital market remains sluggish, biotechs are signing ever-richer licensing deals with Big Pharma backers, and the average value of upfront payments jumped 37% across the industry last quarter, according to a report, paced by some lucrative deals in the earliest stages of development.
The Danish biotech Egalet has pocketed a $10 million upfront payment from Shionogi to collaborate on the development of abuse-resistant hydrocodone opioid pain drugs.
An investigative team at the University of Zurich says they have nailed down some clear proof-of-principle evidence in animal studies that a combination of interleukin-12 used in a combo immunotherapy approach offers a promising new avenue of research in tackling lethal cases of brain cancer.
AstraZeneca hammered the local economy in Loughborough, U.K., in 2011 when it closed down a 70-acre research campus and ditched 1,200 jobs in the process. Now developers are working to pick up the pieces, rebranding the drug development ghost town with hopes of luring new tenants while Big Pharma moves away from the model of secluded R&D.
Ten years after BTG weathered a tempest as the FDA erected a barrier to its new treatment for varicose veins, the British biotech company has finally gained U.S. approval for its product and confidently predicts it can register peak sales of $500 million a year.
Merrimack Pharmaceuticals and its partners at Sanofi are back with another trial failure to report on the biotech's lead drug, MM-121. Combined with exemestane, the drug failed to improve progression-free survival among a group of ER/PR+, HER2 negative breast cancer patients.
Earlier this year, Bayer happily heralded the FDA's approval of Xofigo for castration-resistant prostate cancer as an important milestone for its steadily growing portfolio of cancer therapies. And now the German pharma company has set its sights on bagging Algeta--the Norwegian company that discovered the therapy and subsequently partnered with Bayer--for $2.4 billion.